ARTICLE: A Transatlantic Comparison of Patient-Reported Access to and Use of Aspirin in Contemporary Preventive Cardiology
AUTHORS: Alan P Jacobsen, Zi Lun Lim, Blair Chang, Kaleb D Lambeth, Thomas M Das, Colin Gorry, Michael McCague, William Wijns, Patrick W J C Serruys, Roger S Blumenthal, Seth S Martin, John W McEvoy
JOURNAL: J Am Coll Cardiol. 2021 Sep 14;78(11):1193-1195. doi: 10.1016/j.jacc.2021.07.015.
Aspirin is effective in the secondary prevention of cardiovascular disease (CVD). By contrast, aspirin’s role in primary prevention is controversial, with the most recent data demonstrating a reduction in nonfatal CVD that is largely counterbalanced by excess risk of major bleeding (1). Current guidelines for primary prevention aspirin differ on both sides of the Atlantic (2,3). Accordingly, patients may have heard mixed messages about aspirin use in primary prevention, and some may even now be uncertain about its use in the secondary prevention of CVD. We aimed to survey contemporary patients with a history of or risk factors for CVD to evaluate their use and understanding of aspirin. We enrolled participants in the United States and Europe so that comparisons could be made in responses by location.
For the full article, click here.
